Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.48 |
| ▸ | AURKA | O14965 | 3/20 | 0.45 |
| ▸ | CDK2 | P24941 | 3/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.43 |
| ▸ | TTK | P33981 | 2/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.43 |
| ▸ | SRC | P12931 | 5/20 | 0.42 |
| ▸ | EGFR | P00533 | 3/20 | 0.42 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | ABL2 | P42684 | 2/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL356179 | 0.93 | CYP3A4 (0.56) | CYP3A4CYP2C9GPR119MKNK1SRC | |
| SCHEMBL10171992 | 0.90 | GPR119 (0.43) | CYP3A4CYP2C9GPR119CDK2ERBB2 | |
| SCHEMBL10172602 | 0.87 | CYP3A4 (0.66) | CYP3A4CYP2C9GPR119 | |
| SCHEMBL355859 | 0.87 | CYP3A4 (0.54) | CYP3A4CYP2C9GPR119MKNK1SRC | |
| SCHEMBL10172675 | 0.85 | CYP3A4 (0.48) | CYP3A4CYP2C9GPR119MKNK1SRC | |
| SCHEMBL10139804 | 0.85 | SRC (0.43) | CYP3A4CYP2C9GPR119SRCEGFR | |
| SCHEMBL356564 | 0.85 | GPR119 (0.54) | CYP3A4CYP2C9GPR119MKNK1SRC | |
| SCHEMBL10172673 | 0.84 | CYP3A4 (0.56) | CYP3A4CYP2C9GPR119MKNK1SRC | |
| SCHEMBL10172677 | 0.83 | CYP3A4 (0.51) | CYP3A4CYP2C9GPR119MKNK1SRC | |
| SCHEMBL355058 | 0.82 | GPR119 (0.48) | CYP3A4CYP2C9GPR119ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | GPR119, GPR139, HCAR1 | CYP3A4 2136/4885CYP2C9 1147/4885GPR119 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.